Clinical Trial Update: The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating a 12-week SOF/VEL regimen with prophylactic TAF in treatment-naïve genotype 1-6 HCV/HBV coinfected adults, with or without compensated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Hepatitis C

Drugs mentioned

• SOF/VEL (Sofosbuvir/Velpatasvir)
• TAF (tenofovir alafenamide)

Snippet

Sponsor: Peking University First Hospital | Conditions: Chronic Hepatitis C, Chronic Hepatitis B | Phase 4 | Status: UNKNOWN